Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

FDA Approves Avastin for Most Common Kidney Cancer


In combination with a second drug

TUESDAY, Aug. 4 (HealthDay News) -- The drug Avastin has been approved in the United States for treating people with metastatic renal cell carcinoma, the most common form of kidney cancer.

The U.S. Food and Drug Administration approved Avastin to be used in combination with the drug interferon-alpha, Agence France Presse reported.

A study found that people treated with a combination of the drugs lived nearly twice as long without disease progression compared to people treated with only interferon-alpha.

Since the end of 2007, Avastin has been available in Europe as a first-line treatment for advanced kidney cancer, AFP reported. Last week, European officials approved the drug for treatment of breast cancer.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision